Please provide your email address to receive an email when new articles are posted on . Patients with bullous pemphigoid experienced increases in cardiovascular mortality risk at 1, 3 and 5 years ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Please provide your email address to receive an email when new articles are posted on . Sustained disease remission occurred in 20% of the study cohort vs. 4% of the placebo group at week 36. 41% of ...

More patients treated with dupilumab experienced sustained disease remission and itch reduction at week 36 compared with those who received placebo. The Food and Drug Administration (FDA) has approved ...

Study met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...

Past research shows no meaningfully increased risk of venous thromboembolism (VTE) in patients with more common chronic inflammatory skin diseases. Bullous pemphigoid (BP) is associated with a 2-fold ...

ENGLEWOOD CLIFFS, N.J.--(BUSINESS WIRE)--Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory ...

DUBLIN--(BUSINESS WIRE)--The "Bullous pemphigoid - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering. The "Bullous Pemphigoid - Pipeline Insight, 2023" report ...

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary ...

Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...

“Bullous pemphigoid is a debilitating skin disease with a high mortality rate due to infection. Dupixent is the first medication to show significant and robust impacts in this patient population,” ...